Page last updated: 2024-08-24

thiazolyl blue and dactolisib

thiazolyl blue has been researched along with dactolisib in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ishikawa, D; Matsumoto, K; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S1
Fu, W; Hu, L; Zhu, W1

Other Studies

2 other study(ies) available for thiazolyl blue and dactolisib

ArticleYear
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
    International journal of cancer, 2013, Jul-15, Volume: 133, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome

2013
NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3.
    Cancer biotherapy & radiopharmaceuticals, 2013, Volume: 28, Issue:9

    Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Flow Cytometry; Humans; Imidazoles; Male; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Quinolines; Radiation Tolerance; Radiation, Ionizing; Radiopharmaceuticals; Receptors, Androgen; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases

2013
chemdatabank.com